Recent Finacing
Recent Raise
Amphivena, a clinical-stage immuno-oncology developer, is advancing AMV564, a bivalent CD33/CD3 T cell engager that targets MDSCs while sparing neutrophils/monocytes, in Phase 1 AML/MDS and solid tumor trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Amphivena Therapeutics.
